Biohaven Ltd.: Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300
Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of IgG, differentiating Biohaven's new small molecule class of degraders from the monoclonal ...
PipelineReview.com1d
Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300
NEW HAVEN, CT, USA I March 3, 2025 I Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, ...
The Lancet6d
Proteomic organ-specific ageing signatures and 20-year risk of age-related diseases: the Whitehall II observational cohort study
Advanced proteomic organ ageing is associated with the long-term risk of age-related diseases. In most cases, faster ageing ...